NQO1 and lung carcinoma: Previous findings on NQO1 include that it determines cellular sensitivity to the antitumor agent napabucasin in many cancer cell lines (Guo et al., 2020), is a potential poor prognostic biomarker, and is a promising therapeutic target for patients with lung cancers (Cheng et al., 2018; Siegel et al., 2012), and that mutations in NQO1 are associated with susceptibility to various forms of cancer.